Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7322
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    90,632.07
    -1,184.47 (-1.29%)
     

  • CMC Crypto 200

    1,425.00
    +10.24 (+0.72%)
     

  • GOLD FUTURES

    2,336.60
    -5.50 (-0.23%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,676.00
    +69.25 (+0.39%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    0.0000 (0.00%)
     

Stocks in play: Numinus Wellness Inc.

Baystreet.ca
·1 min read

Has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract, previously announced on April 26, 2021. This major milestone advances Numinus' investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office. With its licensed capabilities, Numinus' lab will produce, package and label both PSYBINA RX ™ and the Psilocybin comparator for the clinical trial which will be conducted at Numinus' clinical site in Vancouver, British Columbia on 14 healthy volunteers. Numinus Wellness Inc. shares V.NUMI are trading unchanged at $0.74.

Read: